Your response to this drug may vary based on your medical history and diagnosis. Dupixent’s mechanism of action (how it works) is to target specific components in your immune system. When ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD ...
Dupixent becomes the first-ever targeted therapy ... There is also the prospect of another therapy with a new mechanism of action in the next year or two after Amgen and AstraZeneca’s TSLP ...
The drug’s mechanism of action simultaneously inhibits IL-4 and IL-13, which Sanofi says makes it a powerful treatment for type 2 inflammation in multiple diseases. Dupixent has already picked ...
The comparable figures from Dupixent trials are as high as 36% after 16 weeks. Amgen sees an opportunity for a drug with a different mechanism of action, citing evidence about how often patients ...
Dupixent (dupilumab) is a brand-name subcutaneous injection that’s prescribed for atopic dermatitis, asthma, and more. It works to treat those conditions by blocking proteins that cause ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback